Schlachter, N., Lichtman, E., Palmer, A. (2025). Daratumumab provides equivalent survival benefits in first-line and second-line treatment of transplant-ineligible multiple myeloma: A computational analysis of Phase 3 trials in first-line and second-line settings.. Blood. https://doi.org/10.1182/blood-2025-4011